Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Korea Approval For Nuvaxovid, Japan Filing For Paxlovid

Executive Summary

More progress for vaccines and oral antivirals in Asia as South Korea issues an approval for Novavax's vaccine, Pfizer files for Japanese approval of Paxlovid, and SK bio progresses late-stage trials of its recombinant vaccine. 

You may also be interested in...



Coronavirus Update: Japan Approves Lagevrio, Korea Clears Paxlovid

Oral antivirals make progress in Asia as Japan issues emergency approval to Merck's Lagevrio in a matter of weeks and South Korea clears Pfizer's contender Paxlovid. Vaccines also move forward in both countries with deals for boosters, new supply agreements and the advancement of home-grown candidates.  

Executives On The Move: Changes At SpineThera, Morphic Holding and More

Recent executive changes in the industry include C-suite changes at Zentalis Pharmaceuticals and Morphic Holding. Meanwhile, new directors were appointed at SpineThera and Avenue Therapeutics, among others.

Executives On The Move: Changes At Alligator Bioscience, Legend Biotech and More

Recent executive changes in the industry include C-suite changes at Legend Biotech and Seagen. Meanwhile, new directors were appointed at Alligator Bioscience and Kintor Pharmaceutical, among others.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145705

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel